Patients can enter clinical trials before, during or after starting their treatment.
The internationally recognized experts at the OSUCCC – James believe the best way to treat patients and manage their disease successfully is to be at the forefront of delivering the latest, most effective treatments available and by working with nationally and internationally renowned experts to develop the newest and best amyloidosis treatments and programs.
The OSUCCC – James has more than 500 open clinical trials at any given time, with some of the world’s latest discoveries available to clinical trial patients right here in Columbus, Ohio. In fact, patients have access to more of this nation’s leading edge, targeted treatments and clinical trials here than at nearly any other hospital in the region as well as access to some of the most advanced, targeted treatments and drugs.
Additionally, the OSUCCC – James is one of only four U.S. cancer centers funded by the National Cancer Institute (NCI) to conduct phase I and phase II clinical trials. These trials go only to centers that demonstrate an exemplary capacity for research and clinical care, the expertise to deliver the latest in treatments and the infrastructure to interpret and track treatment results.
The OSUCCC – James and Ohio State have more than 300 cancer researcher scientists dedicated to understanding what makes each patient’s disease grow, spread or reoccur. Because of the OSUCCC – James’ NCI phase I and phase II approvals, these experts can move research discoveries into clinical trials and get them to patients sooner, which can mean improved outcomes, faster responses and fewer side effects.
If you have been diagnosed with amyloidosis, would like a second opinion or would like to speak with an amyloidosis specialist, please call The James Line at 800-293-5066 or 614-293-5066 to make an appointment.
If you are a health care provider and would like to find out more, refer a patient or schedule a consult, please call 614-293-3196.